All In MedTech

Device Trial Radar · NCT05765266

ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

May 13, 2024

Primary completion

Jul 15, 2025

Study completion Feb 9, 2026

Sponsor

Lead sponsor
Arthrex, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Mar 13, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, multicenter (up to 4 sites), randomized, double-blind, two-arm study. Forty-five (45) patients will be randomized to receive a single 4-6 ml intra-articular (IA) injection of either the output of ACP Max™ (n=30) or 6 ml of Depo-Medrol® (methylprednisolone acetate) (n=15).

Conditions

  • Knee Osteoarthritis

Interventions

  • ACP Max™Device

    Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™

  • Depo-Medrol®Device

    Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 6 months
  2. Adverse EventsTime frame: 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • The Center for Clinical Research

    Winston-Salem, North Carolina

  • AMR Knoxville

    Knoxville, Tennessee

  • Spectrum Medical, Inc.

    Danville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.